Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment

被引:12
作者
Joyce, Daniel D. D. [1 ]
Schulte, Phillip J. J. [2 ]
Kwon, Eugene D. D. [1 ]
Dusetzina, Stacie B. B. [3 ,4 ]
Moses, Kelvin A. A. [5 ]
Sharma, Vidit [1 ]
Penson, David F. F. [5 ,6 ]
Tilburt, Jon C. C. [7 ,8 ,9 ]
Boorjian, Stephen A. A. [1 ]
机构
[1] Mayo Clin, Dept Urol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Div Clin Trials & Biostat, Rochester, MN 55905 USA
[3] Vanderbilt Univ, Dept Hlth Policy, Med Ctr, Nashville, TN USA
[4] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Vanderbilt, TN USA
[5] Vanderbilt Univ, Dept Urol, Med Ctr, Nashville, TN USA
[6] Vet Affairs Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA
[7] Mayo Clin, Div Gen Internal Med, Scottsdale, AZ USA
[8] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN 55905 USA
[9] Mayo Clin, Biomed Ethics Res Program, Rochester, MN 55905 USA
关键词
prostatic neoplasms; neoplasm metastasis; costs and cost analysis; ORAL ANTICANCER MEDICATIONS; ASSISTANCE PROGRAMS; HIGH-PRICE; SURVIVORS; DRUGS; ADHERENCE; BURDEN; COSTS;
D O I
10.1097/JU.0000000000003506
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose:Assessments of financial toxicity among patients with metastatic prostate cancer are lacking. Using patient surveys, we sought to identify coping mechanisms and assess characteristics associated with lower financial toxicity.Materials and Methods:Surveys were administered to all patients seen at a single center's Advanced Prostate Cancer Clinic over a 3-month period. Surveys included the COST-FACIT (COmprehensive Score for Financial Toxicity) and coping mechanism questionnaires. Patients with metastatic disease (lymph nodes, bone, visceral) were included for analysis. Coping mechanisms were compared between patients experiencing low (COST-FACIT >24) vs high (COST-FACIT & LE;24) financial toxicity using Fisher's exact test. Multivariable linear regression was used to evaluate characteristics associated with lower financial toxicity.Results:Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity. In multivariable analysis, characteristics associated with lower financial toxicity included older age (estimate: 0.36, 95%CI: 0.21-0.52), applying for patient assistance programs (estimate: 4.42, 95%CI: 1.72-7.11), and an annual income of at least $100,000 (estimate: 7.81, 95%CI: 0.97, 14.66). Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment.Conclusions:In this cross-sectional study, patients with metastatic prostate cancer and high financial toxicity were more likely to decrease spending on basic goods and leisure activities and use savings to pay for care. Understanding the impact of financial toxicity on patients' lives is crucial to inform shared decision-making and interventions designed to mitigate financial toxicity in this population.
引用
收藏
页码:290 / 298
页数:9
相关论文
共 30 条
[1]   Patient-physician communication about out-of-pocket costs [J].
Alexander, GC ;
Casalino, LP ;
Meltzer, DO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :953-958
[2]   Patient-oncologist cost communication, financial distress, and medication adherence [J].
Bestvina, Christine M. ;
Zullig, Leah L. ;
Rushing, Christel ;
Chino, Fumiko Ladd ;
Samsa, Greg ;
Altomare, Ivy ;
Tulsky, James A. ;
Ubel, Peter A. ;
Schrag, Deborah ;
Nicolla, Jonathan ;
Abernethy, Amy Pickar ;
Peppercorn, Jeffrey M. ;
Zafar, Yousuf .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)
[3]   Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer [J].
Caram, Megan E. V. ;
Oerline, Mary K. ;
Dusetzina, Stacie ;
Herrel, Lindsey A. ;
Modi, Parth K. ;
Kaufman, Samuel R. ;
Skolarus, Ted A. ;
Hollenbeck, Brent K. ;
Shahinian, Vahakn .
CANCER, 2020, 126 (23) :5050-5059
[4]   Drug Company-Sponsored Patient Assistance Programs: A Viable Safety Net? [J].
Choudhry, Niteesh K. ;
Lee, Joy L. ;
Agnew-Blais, Jessica ;
Corcoran, Colleen ;
Shrank, William H. .
HEALTH AFFAIRS, 2009, 28 (03) :827-834
[5]   Drug Pricing and Value in Oncology [J].
Danzon, Patricia M. ;
Taylor, Erin .
ONCOLOGIST, 2010, 15 :24-31
[6]   Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) [J].
de Souza, Jonas A. ;
Yap, Bonnie J. ;
Wroblewski, Kristen ;
Blinder, Victoria ;
Araujo, Fabiana S. ;
Hlubocky, Fay J. ;
Nicholas, Lauren H. ;
O'Connor, Jeremy M. ;
Brockstein, Bruce ;
Ratain, Mark J. ;
Daugherty, Christopher K. ;
Cella, David .
CANCER, 2017, 123 (03) :476-484
[7]   Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients [J].
Delgado-Guay, Marvin ;
Ferrer, Jeanette ;
Rieber, Alyssa G. ;
Rhondali, Wadih ;
Tayjasanant, Supakarn ;
Ochoa, Jewel ;
Cantu, Hilda ;
Chisholm, Gary ;
Williams, Janet ;
Frisbee-Hume, Susan ;
Bruera, Eduardo .
ONCOLOGIST, 2015, 20 (09) :1092-1098
[8]   Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions [J].
Dusetzina, Stacie B. ;
Huskamp, Haiden A. ;
Rothman, Russell L. ;
Pinheiro, Laura C. ;
Roberts, Andrew W. ;
Shah, Nilay D. ;
Walunas, Theresa L. ;
Wood, William A. ;
Zuckerman, Autumn D. ;
Zullig, Leah L. ;
Keating, Nancy L. .
HEALTH AFFAIRS, 2022, 41 (04) :487-496
[9]   Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019 [J].
Dusetzina, Stacie B. ;
Huskamp, Haiden A. ;
Keating, Nancy L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (20) :2025-2027
[10]   Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia [J].
Dusetzina, Stacie B. ;
Winn, Aaron N. ;
Abel, Gregory A. ;
Huskamp, Haiden A. ;
Keating, Nancy L. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) :306-311